Treatment intensity and characteristics of MRSA infection in CF

J Cyst Fibros. 2011 May;10(3):201-6. doi: 10.1016/j.jcf.2011.02.004. Epub 2011 Mar 21.


Background: Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and interchange of hospital-associated strains carrying the staphylococcal chromosomal cassette mec-II (SCCmec-II) with those in the community (SCCmec-IV) has increased. This study assesses the impact of MRSA and different MRSA types on clinical outcomes, medication use, and antibiotic sensitivities.

Methods: MRSA isolates from CF patients at our center were typed by SCCmec- and pv(l) status. Patient characteristics, lung function and nutrition are compared between MRSA types and to age, gender and Pseudomonas aeruginosa matched patients with chronic methicillin sensitive S. aureus (MSSA) infection.

Results: Seventy-two percent of patients carry pv(l) negative SCCmec-II isolates. Seventeen percent of all MRSA were SCCmec-IV pv(l) positive (USA300). These patients were younger and fewer had chronic P. aeruginosa infection, whereas pv(l)-negative SCCmec-IV isolates show highest antibiotic resistance. Nutritional outcomes and FEV1 percent predicted (75.1 ± 2.7 versus 77.9 ± 2.7) did not differ in patients with MRSA compared to those with MSSA but MRSA patients received more pulmonary maintenance but not oral antibiotic medications.

Conclusion: Patients with chronic MRSA are treated more intensely than age, gender and Pseudomonas aeruginosa matched MSSA-positive patients but clinical characteristics within MRSA patients vary depending on MRSA types.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / therapeutic use
  • Body Mass Index
  • Child
  • Chronic Disease
  • Community-Acquired Infections
  • Cross Infection / epidemiology
  • Cystic Fibrosis / microbiology*
  • Female
  • Humans
  • Linear Models
  • Longitudinal Studies
  • Male
  • Methicillin / therapeutic use
  • Methicillin-Resistant Staphylococcus aureus* / classification
  • Methicillin-Resistant Staphylococcus aureus* / genetics
  • Microbial Sensitivity Tests
  • Prospective Studies
  • Pseudomonas Infections / complications
  • Pseudomonas aeruginosa
  • Severity of Illness Index
  • Staphylococcal Infections / complications*
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / physiopathology*
  • Staphylococcus aureus / drug effects
  • Treatment Outcome
  • Young Adult


  • Anti-Bacterial Agents
  • Methicillin